Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2017

Open Access 01-12-2017 | Study protocol

Study protocol: Insight 46 – a neuroscience sub-study of the MRC National Survey of Health and Development

Authors: Christopher A. Lane, Thomas D. Parker, Dave M. Cash, Kirsty Macpherson, Elizabeth Donnachie, Heidi Murray-Smith, Anna Barnes, Suzie Barker, Daniel G. Beasley, Jose Bras, David Brown, Ninon Burgos, Michelle Byford, M. Jorge Cardoso, Ana Carvalho, Jessica Collins, Enrico De Vita, John C. Dickson, Norah Epie, Miklos Espak, Susie M. D. Henley, Chandrashekar Hoskote, Michael Hutel, Jana Klimova, Ian B. Malone, Pawel Markiewicz, Andrew Melbourne, Marc Modat, Anette Schrag, Sachit Shah, Nikhil Sharma, Carole H. Sudre, David L. Thomas, Andrew Wong, Hui Zhang, John Hardy, Henrik Zetterberg, Sebastien Ourselin, Sebastian J. Crutch, Diana Kuh, Marcus Richards, Nick C. Fox, Jonathan M. Schott

Published in: BMC Neurology | Issue 1/2017

Login to get access

Abstract

Background

Increasing age is the biggest risk factor for dementia, of which Alzheimer’s disease is the commonest cause. The pathological changes underpinning Alzheimer’s disease are thought to develop at least a decade prior to the onset of symptoms. Molecular positron emission tomography and multi-modal magnetic resonance imaging allow key pathological processes underpinning cognitive impairment – including β-amyloid depostion, vascular disease, network breakdown and atrophy – to be assessed repeatedly and non-invasively. This enables potential determinants of dementia to be delineated earlier, and therefore opens a pre-symptomatic window where intervention may prevent the onset of cognitive symptoms.

Methods/design

This paper outlines the clinical, cognitive and imaging protocol of “Insight 46”, a neuroscience sub-study of the MRC National Survey of Health and Development. This is one of the oldest British birth cohort studies and has followed 5362 individuals since their birth in England, Scotland and Wales during one week in March 1946. These individuals have been tracked in 24 waves of data collection incorporating a wide range of health and functional measures, including repeat measures of cognitive function. Now aged 71 years, a small fraction have overt dementia, but estimates suggest that ~1/3 of individuals in this age group may be in the preclinical stages of Alzheimer’s disease. Insight 46 is recruiting 500 study members selected at random from those who attended a clinical visit at 60–64 years and on whom relevant lifecourse data are available. We describe the sub-study design and protocol which involves a prospective two time-point (0, 24 month) data collection covering clinical, neuropsychological, β-amyloid positron emission tomography and magnetic resonance imaging, biomarker and genetic information. Data collection started in 2015 (age 69) and aims to be completed in 2019 (age 73).

Discussion

Through the integration of data on the socioeconomic environment and on physical, psychological and cognitive function from 0 to 69 years, coupled with genetics, structural and molecular imaging, and intensive cognitive and neurological phenotyping, Insight 46 aims to identify lifetime factors which influence brain health and cognitive ageing, with particular focus on Alzheimer’s disease and cerebrovascular disease. This will provide an evidence base for the rational design of disease-modifying trials.
Appendix
Available only for authorised users
Literature
1.
Office of National Statistics. Deaths Registered in England and Wales; 2016. p. 1–15.
2.
Prince M, Albanese E, Guerchet M, Prina M, Richard Pender C, Ferri C, et al. World Alzheimer. Report 2014 Dementia and Risk Reduction an Analysis of Protective and Modifiable Factors. 2014.
3.
Alzheimer’s Association. Changing the Trajectory of Alzheimer’s Disease: A National Imperative. Alzheimer’s Assoc. 2010:1–17.
4.
Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351–7.PubMedCrossRef
5.
Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367:795–804.PubMedPubMedCentralCrossRef
6.
Villemagne VL. Burnham S, Bourgeat P, Brown B, Ellis K a, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67.PubMedCrossRef
7.
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–92.PubMedPubMedCentralCrossRef
8.
Jack CR, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, et al. Age-specifi c population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross- sectional study. Lancet Neurol 2014;13:997–1005.
9.
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29.PubMedCrossRef
10.
Reiman EM, Langbaum JBS, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, et al. Alzheimer’s prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011;26(Suppl 3):321–9.PubMedPubMedCentral
11.
Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol. 2013;169:737–43.PubMedCrossRef
12.
Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6:228fs13.PubMedPubMedCentralCrossRef
13.
Mormino EC. The relevance of Beta-Amyloid on markers of Alzheimer’s disease in clinically normal individuals and factors that influence these associations. Neuropsychol Rev. 2014:300–12.
14.
Brodaty H, Mothakunnel A, de Vel-Palumbo M, Ames D, Ellis KA, Reppermund S, et al. Influence of population versus convenience sampling on sample characteristics in studies of cognitive aging. Ann Epidemiol. 2014;24:63–71.PubMedCrossRef
15.
Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, et al. Common polygenic variation enhances risk prediction for Alzheimer’s disease. Brain. 2015;138:3673–84.PubMedPubMedCentralCrossRef
16.
Xu W, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, et al. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2015;86:1299–306.PubMed
17.
Kuh D, Pierce M, Adams J, Deanfield J, Ekelund U, Friberg P, et al. Cohort profile: updating the cohort profile for the MRC National Survey of health and development: a new clinic-based data collection for ageing research. Int J Epidemiol. 2011;40
18.
Wadsworth M, Kuh D, Richards M, Hardy R. Cohort profile: the 1946 National Birth Cohort (MRC National Survey of health and development). Int J Epidemiol. 2006;35:49–54.PubMedCrossRef
19.
Kuh D, Wong A, Shah I, Moore A, Popham M, Curran P, et al. The MRC National Survey of health and development reaches age 70: maintaining participation at older ages in a birth cohort study. Eur J Epidemiol. 2016;31:1135–47.PubMedPubMedCentralCrossRef
20.
Alzheimer’s Association. Alzheimer’s association report: 2014 Alzheimers disease facts and figures. Alzheimers Dement. 2014;10:e47–92.CrossRef
21.
Hardy R, Ghosh AK, Deanfield J, Kuh D, Hughes AD. Birthweight, childhood growth and left ventricular structure at age 60–64 years in a British birth cohort study. Int J Epidemiol. 2016;45(4):1091–102.PubMedCrossRef
22.
23.
Harkins K, Sankar P, Sperling R, Grill JD, Green RC, Johnson KA, et al. Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther. 2015;7:26.PubMedPubMedCentralCrossRef
24.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–4.PubMedPubMedCentralCrossRef
25.
Spielberger. State-Trait Anxiety Inventory: A comprehensive bibliography. 1983.
26.
Eke PI, Dye BA, Wei L, Slade GD, Thornton-Evans GO, Beck JD, et al. Self-reported measures for surveillance of periodontitis. J Dent Res. 2013;92:1041–7.PubMedCrossRef
27.
Cerajewska TL, Davies M, West NX. Periodontitis: a potential risk factor for Alzheimer’s disease. BDJ Nature Publishing Group. 2015;218:29–34.
28.
29.
Bishop DVM. Cerebral asymmetry and language development: cause, correlate, or consequence? Sci Eur PMC Funders. 2013;340:1230531.
30.
Postuma RB, Arnulf I, Hogl B, Iranzo A, Miyamoto T, Dauvilliers Y, et al. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov Disord. 2012;27:913–6.PubMedPubMedCentralCrossRef
31.
Rami L. Mollica M a, García-Sanchez C, Saldaña J, Sanchez B, Sala I, et al. The subjective cognitive decline questionnaire (SCD-Q): a validation study. J Alzheimers Dis. 2014;41:453–66.
32.
Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10:844–52.PubMedPubMedCentralCrossRef
33.
Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, Grant E, et al. The AD8: a brief informant interview to detect dementia. Neurology. 2005;65:559–64.PubMedCrossRef
34.
Galvin JE, Roe CM, Xiong C, Morris JC. Validity and reliability of the AD8 informant interview in dementia. Neurology. 2006;67:1942–8.PubMedCrossRef
35.
Verghese J, Robbins M, Holtzer R, Zimmerman M, Wang C, Xue X, et al. Gait dysfunction in mild cognitive impairment syndromes. J Am Geriatr Soc Blackwell Publishing Inc. 2008;56:1244–51.CrossRef
36.
Buracchio T, Dodge HH, Howieson D, Wasserman D, Kaye J. The trajectory of gait speed preceding mild cognitive impairment. Arch Neurol. 2010;67:980–6.PubMedPubMedCentralCrossRef
37.
Hausdorff JM, Yogev G. Cognitive function may be important for fall injury prevention trials. J Am Geriatr Soc. 2006;54:865.PubMedCrossRef
38.
Rota V, Perucca L, Simone A, Tesio L. Walk ratio (step length/cadence) as a summary index of neuromotor control of gait: application to multiple sclerosis. Int J Rehabil Res Int Zeitschrift für Rehabil Rev Int Rech réadaptation. 2011;34:265–9.
39.
Collett J, Esser P, Khalil H, Busse M, Quinn L, DeBono K, et al. Insights into gait disorders: walking variability using phase plot analysis. Huntington’s disease Gait Posture. 2014;40:694–700.PubMedCrossRef
40.
Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA. Parkinsonianlike signs and risk of incident Alzheimer disease in older persons. Arch Neurol. 2003;60:539–44.PubMedCrossRef
41.
Richards M, Stern Y, Mayeux R. Subtle extrapyramidal signs can predict the development of dementia in elderly individuals. Neurology. 1993;43:2184–8.PubMedCrossRef
42.
Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129–70.PubMedCrossRef
43.
Noyce AJ, Nagy A, Acharya S, Hadavi S, Bestwick JP, Fearnley J, et al. Bradykinesia-akinesia incoordination test: validating an online keyboard test of upper limb function. PLoS One. 2014;9
44.
Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71:961–70.PubMedPubMedCentralCrossRef
45.
Hsieh S, Schubert S, Hoon C, Mioshi E, Hodges JR. Validation of the Addenbrooke’s Cognitive Examination III in Frontotemporal Dementia and Alzheimer’s Disease. Dementia and Geriatric Cognitive Disorders. 2013;36(3–4):242–50.
46.
Silverwood RJ, Richards M, Pierce M, Hardy R, Sattar N, Ferro C, et al. Cognitive and kidney function: results from a British birth cohort reaching retirement age. PLoS One. 2014;9:e86743.PubMedPubMedCentralCrossRef
47.
48.
Wechsler D. Wechsler memory scale-revised edition. 1987.
49.
Wechsler D. Wechsler Adult Intelligence Scale–Revised. 1981.
50.
Wechsler D. The Wechsler abbreviated scale of intelligence. San Antonio: The Psychological Corporation; 1999.
51.
Shallice T, Stuss DT, Picton TW, Alexander MP, Gillingham S. Multiple effects of prefrontal lesions on task-switching. Front Hum Neurosci. 2007;1:2.PubMed
52.
Aron AR, Monsell S, Sahakian BJ, Robbins TW. A componential analysis of task-switching deficits associated with lesions of left and right frontal cortex. Brain. 2004;127:1561–73.PubMedCrossRef
53.
54.
Castel AD, Balota DA, Hutchison KA, Logan JM, Yap MJ. Spatial attention and response control in healthy younger and older adults and individuals with Alzheimer’s disease: evidence for disproportionate selection impairments in the Simon task. Neuropsychology. 2007;21:170–82.PubMedCrossRef
55.
Hutchison KA, Balota DA, Duchek JM, Ducheck JM. The utility of Stroop task switching as a marker for early-stage Alzheimer’s disease. Psychol Aging. 2010;25:545–59.PubMedPubMedCentralCrossRef
56.
Pertzov Y, Miller TD, Gorgoraptis N, Caine D, Schott JM, Butler C, et al. Binding deficits in memory following medial temporal lobe damage in patients with voltage-gated potassium channel complex antibody-associated limbic encephalitis. Brain. 2013;136:2474–85.PubMedPubMedCentralCrossRef
57.
58.
Parra MA, Abrahams S, Logie RH, Méndez LG, Lopera F, Della SS. Visual short-term memory binding deficits in familial Alzheimer’s disease. Brain. 2010;133:2702–13.PubMedCrossRef
59.
Liang Y, Pertzov Y, Nicholas JM, Henley SMD, Crutch S, Woodward F, et al. Visual short-term memory binding deficit in familial Alzheimer’s disease. Cortex. 2016;78:150–64.PubMedPubMedCentralCrossRef
60.
Pertzov Y, Heider M, Liang Y, Husain M. Effects of healthy ageing on precision and binding of object location in visual short term memory. Psychol Aging American Psychological Association. 2015;30:26–35.CrossRef
61.
Say MJ, Jones R, Scahill RI, Dumas EM, Coleman A, Santos RCD, et al. Visuomotor integration deficits precede clinical onset in Huntington’s disease. Neuropsychologia Ltd. 2011;49:264–70.CrossRef
62.
Papp KV, Amariglio RE, Dekhtyar M, Roy K, Wigman S, Bamfo R, et al. Development of a psychometrically equivalent short form of the face-name associative memory exam for use along the early Alzheimer’s disease trajectory. Clin. Neuropsychol. 2014;28:771–85.
63.
Rentz DM, Amariglio RE, Becker JA, Frey M, Olson LE, Frishe K, et al. Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia. 2011;49:2776–83.PubMedPubMedCentralCrossRef
64.
Forster S, Lavie N. Failures to ignore entirely irrelevant distractors: the role of load. J Exp Psychol Appl American Psychological Association. 2008;14:73–83.CrossRef
65.
Forster S, Lavie N. Attentional capture by entirely irrelevant distractors. Vis Cogn. 2008;16:200–14.CrossRef
66.
Devanand DP, Lee S, Manly J, Andrews H, Schupf N, Doty RL, et al. Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community. Neurology. 2015:182–9.
67.
Gates GA, Anderson ML, McCurry SM, Feeney MP, Larson EB. Central auditory dysfunction as a harbinger of Alzheimer dementia. Arch Otolaryngol Head Neck Surg. 2011;137:390–5.PubMedPubMedCentralCrossRef
68.
Lin FR, Albert M. Hearing loss and dementia – who is listening? Aging Ment. Health. 2014;18:671–3.
69.
Hardy CJD, Marshall CR, Golden HL, Clark CN, Mummery CJ, Griffiths TD, et al. Hearing and dementia. J Neurol. 2016:1–16.
70.
Albers MW, Gilmore GC, Kaye J, Murphy C, Wingfield A, Bennett D a., et al. At the interface of sensory and motor dysfunctions and Alzheimer’s disease. Alzheimer’s Dement. 2014; 1–29.
71.
Bastawrous A, Rono HK, Livingstone IAT, Weiss HA, Jordan S, Kuper H, et al. Development and validation of a Smartphone-based visual acuity test (Peek acuity) for clinical practice and community-based fieldwork. JAMA Ophthalmol. 2015;133:930–7.PubMedPubMedCentralCrossRef
72.
Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav. 1984;32:489–502.PubMedCrossRef
73.
British Society of Audiology. Recommended Procedure bone-conduction threshold audiometry with and without masking. 2011
74.
Rosen S, Souza P, Ekelund C, Majeed A a. Listening to speech in a background of other talkers: effects of talker number and noise vocoding. J Acoust Soc Am. 2013;133:2431–43.PubMedPubMedCentralCrossRef
75.
Clark CM. Schneider J a, Bedell BJ, beach TG, bilker WB, Mintun M a, et al. use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275–83.PubMedCrossRef
76.
Burgos N, Cardoso MJ, Modat M, Punwani S, Atkinson D, Arridge SR, et al. CT synthesis in the head & amp; neck region for PET/MR attenuation correction: an iterative multi-atlas approach. EJNMMI Phys. 2015 Dec;2(Suppl 1):A31.PubMedPubMedCentralCrossRef
77.
Burgos N, Cardoso MJ, Thielemans K, Modat M, Pedemonte S, Dickson J, et al. Attenuation correction synthesis for hybrid PET-MR scanners: application to brain studies. IEEE Trans Med Imaging. 2014;33:2332–41.PubMedCrossRef
78.
Mugler JP, Brookeman JR. Rapid three-dimensional T1-weighted MR imaging with the MP-RAGE sequence. J Magn Reson Imaging. 1991 Sep-Oct;1(5):561–7.PubMedCrossRef
79.
80.
Jovicich J, Czanner S, Greve D, Haley E, van der Kouwe A, Gollub R, et al. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. NeuroImage. 2006;30:436–43.PubMedCrossRef
81.
82.
Cardoso MJ, Modat M, Wolz R, Melbourne A, Cash D, Rueckert D, et al. Geodesic information flows: spatially-variant graphs and their application to segmentation and fusion. IEEE Trans Med Imaging. 2015;34:1976–88.PubMedCrossRef
83.
Beckmann CF, DeLuca M, Devlin JT, Smith SM. Investigations into resting-state connectivity using independent component analysis. Philos. Trans R Soc Lond B Biol Sci. 2005;360:1001–13.CrossRef
84.
Mennes M, Jenkinson M, Valabregue R, Buitelaar JK, Beckmann C, Smith S. Optimizing full-brain coverage in human brain MRI through population distributions of brain size. NeuroImage. 2014 Sep;98:513–20.PubMedCrossRef
85.
Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. NeuroImage. 2012;59:2142–54.PubMedCrossRef
86.
Modat M, Ridgway GR, Taylor ZA, Lehmann M, Barnes J, Hawkes DJ, et al. Fast free-form deformation using graphics processing units. Comput Methods Prog Biomed. 2010;98:278–84.CrossRef
87.
Chen G, Saad ZS, Nath AR, Beauchamp MS, Cox RW. FMRI group analysis combining effect estimates and their variances. NeuroImage. 2012;60:747–65.PubMedCrossRef
88.
Glover GH, Li TQ, Ress D. Image-based method for retrospective correction of physiological motion effects in fMRI: RETROICOR. Magn Reson Med. 2000;44:162–7.PubMedCrossRef
89.
Lohmann G, Stelzer J, Neumann J, Ay N, Turner R. “more is different” in functional magnetic resonance imaging: a review of recent data analysis techniques. Brain Connect. 2013;3:223–39.PubMedCrossRef
90.
Hütel M, Melbourne A, Thomas D, Rohrer J and Ourselin S. An overcomplete and efficient ICA for BOLD-fMRI.ISMRM. 2016.
91.
92.
Weston PSJ, Simpson IJA, Ryan NS, Ourselin S, Fox NC. Diffusion imaging changes in grey matter in Alzheimer’s disease: a potential marker of early neurodegeneration. Alzheimers Res Ther. 2015;7:47.PubMedPubMedCentralCrossRef
93.
Zhang H, Schneider T. Wheeler-Kingshott C a., Alexander DC. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. NeuroImage. 2012;61:1000–16.PubMedCrossRef
94.
Feinberg DA, Jakab PD. Tissue perfusion in humans studied by Fourier velocity distribution, line scan, and echo-planar imaging. Magn Reson Med. 1990;16:280–93.PubMedCrossRef
95.
Reese TG, Heid O, Weisskoff RM, Wedeen VJ. Reduction of eddy-current-induced distortion in diffusion MRI using a twice-refocused spin echo. Magn Reson Med. 2003;49:177–82.PubMedCrossRef
96.
Andersson JLR, Sotiropoulos SN. An integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging. NeuroImage. 2016;125:1063–78.PubMedPubMedCentralCrossRef
97.
Daga P, Pendse T, Modat M, White M, Mancini L, Winston GP, et al. Susceptibility artefact correction using dynamic graph cuts: application to neurosurgery. Med Image Anal. 2014;18:1132–42.PubMedCrossRef
98.
Melbourne A, Toussaint N, Owen D, Simpson I, Anthopoulos T, De Vita E, et al. NiftyFit: a software package for multi-parametric model-fitting of 4D magnetic resonance imaging data. Neuroinformatics. 2016;14:319–37.PubMedPubMedCentralCrossRef
99.
Cordonnier C, van der Flier WM, Attems J, Bayer A, Bullock R, Jones R, et al. Brain microbleeds and Alzheimer’s disease: innocent observation or key player? Brain. 2011;134:335–44.PubMedCrossRef
100.
Shoamanesh A, Preis SR, Beiser AS, Vasan RS, Benjamin EJ, Kase CS, et al. Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham heart study. Neurology. 2015;84:825–32.PubMedPubMedCentralCrossRef
101.
Haacke EM, Mittal S, Wu Z, Neelavalli J, Cheng Y-CN. Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol. 2009;30:19–30.PubMedCrossRef
102.
Schweser F, Deistung A, Sommer K, Reichenbach JR. Toward online reconstruction of quantitative susceptibility maps: superfast dipole inversion. Magn Reson Med. 2013;69:1581–93.CrossRef
103.
Vidorreta M, Balteau E, Wang Z, De Vita E, Pastor MA, Thomas DL, et al. Evaluation of segmented 3D acquisition schemes for whole-brain high-resolution arterial spin labeling at 3 T. NMR Biomed. 2014;27:1387–96.PubMedPubMedCentralCrossRef
104.
Alsop DC, Detre JA, Golay X, Günther M, Hendrikse J, Hernandez-Garcia L, et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med. 2015;73:102–16.PubMedCrossRef
105.
Leung KK, Barnes J, Modat M, Ridgway GR, Bartlett JW, Fox NC, et al. Brain MAPS: an automated, accurate and robust brain extraction technique using a template library. NeuroImage. 2011;55:1091–108.PubMedCrossRef
106.
Jorge Cardoso M, Leung K, Modat M, Keihaninejad S, Cash D, Barnes J, et al. STEPS: similarity and truth estimation for propagated segmentations and its application to hippocampal segmentation and brain parcelation. Med Image Anal. 2013;17:671–84.PubMedCrossRef
107.
Malone IB, Leung KK, Clegg S, Barnes J, Whitwell JL, Ashburner J, et al. Accurate automatic estimation of total intracranial volume: a nuisance variable with less nuisance. NeuroImage. 2015;104:366–72.PubMedPubMedCentralCrossRef
108.
Clarkson MJ, Cardoso MJ, Ridgway GR, Modat M, Leung KK, Rohrer JD, et al. A comparison of voxel and surface based cortical thickness estimation methods. NeuroImage. 2011;57:856–65.PubMedCrossRef
109.
Gregoire SM, Chaudhary UJ, Brown MM, Yousry TA, Kallis C, Jäger HR, et al. The Microbleed anatomical rating scale (MARS): reliability of a tool to map brain microbleeds. Neurology. 2009;73:1759–66.PubMedCrossRef
110.
Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318–22.PubMedCrossRef
111.
Prins ND, van Straaten ECW, van Dijk EJ, Simoni M, van Schijndel RA, Vrooman HA, et al. Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetrics. Neurology. 2004;62:1533–9.PubMedCrossRef
112.
Jain S, Sima DM, Ribbens A, Cambron M, Maertens A, Van Hecke W, et al. Automatic segmentation and volumetry of multiple sclerosis brain lesions from MR images. NeuroImage Clin. 2015;8:367–75.PubMedPubMedCentralCrossRef
113.
Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR, Weiner MW, et al. Robust atrophy rate measurement in Alzheimer’s disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. NeuroImage. 2010;50:516–23.PubMedCrossRef
114.
115.
Andrews KA, Modat M, Macdonald KE, Yeatman T, Cardoso MJ, Leung KK, et al. Atrophy rates in asymptomatic Amyloidosis: implications for Alzheimer prevention trials. PLoS One. 2013;8
116.
Erlandsson K, Buvat I, Pretorius PH, Thomas BA, Hutton BF. A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology. Phys Med Biol. 2012;57:R119–59.PubMedCrossRef
117.
O’Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, et al. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement. 2015;11:549–60.PubMedCrossRef
118.
Rohrer JD, Woollacott IOC, Dick KM, Brotherhood E, Gordon E, Fellows A, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016 Sep;27:87(13).
119.
120.
Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, et al. Plasma β-amyloid in Alzheimer’s disease and vascular disease. Sci Rep. 2016;6:26801.PubMedPubMedCentralCrossRef
121.
Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. Plasma concentration of the Neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;3:135–40.PubMedCrossRef
122.
Shah T, Engmann J, Dale C, Shah S, White J, Giambartolomei C, et al. Population genomics of Cardiometabolic traits: Design of the University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol (UCLEB) consortium. PLoS One. 2013;8:e71345.PubMedPubMedCentralCrossRef
123.
Nalls MA, Bras J, Hernandez DG, Keller MF, Majounie E, Renton AE, et al. NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol Aging. 2015;36:1605.e7–12.CrossRef
124.
Gaysina D, Gardner MP, Richards M, Ben-Shlomo Y. Cortisol and cognitive function in midlife: the role of childhood cognition and educational attainment. Psychoneuroendocrinology. 2014;47:189–98.PubMedPubMedCentralCrossRef
125.
Ross JM, Simpson HR. The National Survey of health and development: 1. Educational Attainment Br J Educ Psychol. 1971;41:49–61.CrossRef
126.
Ross JM, Simpson HR. The National Survey of health and development: 2. Rate of school progress between 8 and 15 years and between 15 and 18 years. Br J Educ Psychol 1971; 41:125–135.
127.
Gale CR, Cooper R, Craig L, Elliott J, Kuh D, Richards M, et al. Cognitive function in childhood and lifetime cognitive change in relation to mental wellbeing in four cohorts of older people. PLoS One. 2012;7:e44860.PubMedPubMedCentralCrossRef
128.
Stewart R, Hardy R, Richards M. Associations between skeletal growth in childhood and cognitive function in mid-life in a 53-year prospective birth cohort study. PLoS One. 2015;10:e0124163.PubMedPubMedCentralCrossRef
129.
Albanese E, Hardy R, Wills A, Kuh D, Guralnik J, Richards M. No association between gain in body mass index across the life course and midlife cognitive function and cognitive reserve—the 1946 British birth cohort study. Alzheimers Dement. 2012;8:470–82.PubMedPubMedCentralCrossRef
130.
Richards M, Hardy R, Wadsworth M. Alcohol consumption and midlife cognitive change in the British 1946 birth cohort study. Alcohol Alcohol. 2004;40:112–7.PubMedCrossRef
131.
Richards M, Strachan D, Hardy R, Kuh D, Wadsworth M. Lung function and cognitive ability in a longitudinal birth cohort study. Psychosom Med. 2005;67:602–8.PubMedCrossRef
132.
Richards M, Barnett JH, Xu MK, Croudace TJ, Gaysina D, Kuh D, et al. Lifetime affect and midlife cognitive function: prospective birth cohort study. Br J Psychiatry. 2014;204:194–9.PubMedPubMedCentralCrossRef
133.
Hurst L, Stafford M, Cooper R, Hardy R, Richards M, Kuh D. Lifetime socioeconomic inequalities in physical and cognitive aging. Am J Public Health. 2013;103:1641–8.PubMedPubMedCentralCrossRef
Metadata
Title
Study protocol: Insight 46 – a neuroscience sub-study of the MRC National Survey of Health and Development
Authors
Christopher A. Lane
Thomas D. Parker
Dave M. Cash
Kirsty Macpherson
Elizabeth Donnachie
Heidi Murray-Smith
Anna Barnes
Suzie Barker
Daniel G. Beasley
Jose Bras
David Brown
Ninon Burgos
Michelle Byford
M. Jorge Cardoso
Ana Carvalho
Jessica Collins
Enrico De Vita
John C. Dickson
Norah Epie
Miklos Espak
Susie M. D. Henley
Chandrashekar Hoskote
Michael Hutel
Jana Klimova
Ian B. Malone
Pawel Markiewicz
Andrew Melbourne
Marc Modat
Anette Schrag
Sachit Shah
Nikhil Sharma
Carole H. Sudre
David L. Thomas
Andrew Wong
Hui Zhang
John Hardy
Henrik Zetterberg
Sebastien Ourselin
Sebastian J. Crutch
Diana Kuh
Marcus Richards
Nick C. Fox
Jonathan M. Schott
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2017
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-017-0846-x

Other articles of this Issue 1/2017

BMC Neurology 1/2017 Go to the issue

Research article

Stability and relative validity of the Neuromuscular Disease Impact Profile (NMDIP)

Research article

Low threshold unmyelinated mechanoafferents can modulate pain

Research article

Cigarette smoking is an independent risk factor for post-stroke delirium

Case report

Paroxysmal freezing of gait in a patient with mesial frontal transient ischemic attacks

Research article

Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study

Case report

Isolated non-traumatic, non-aneurysmal convexal subarachnoid hemorrhage in a patient with Evans syndrome